Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic therapy for renal cell carcinoma.

R J Motzer1, P Russo

  • 1Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

The Journal of Urology
|January 27, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influence of sample collection and preanalytical sample processing on the analyses of biological markers in the European multicentre study IDEFICS.

International journal of obesity (2005)·2011
Same author

14C autoradiography with an energy-sensitive silicon pixel detector.

Physics in medicine and biology·2011
Same author

Renal cell carcinoma : clinical features and management.

Methods in molecular medicine·2011
Same author

Impact of genetic variability in nicotinic acetylcholine receptors on nicotine addiction and smoking cessation treatment.

Current medicinal chemistry·2010
Same author

Heritability of body weight: moving beyond genetics.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2010
Same author

Biogenic amines in fermented foods.

European journal of clinical nutrition·2010

Systemic therapy for advanced renal cell carcinoma, including interferon-alpha and interleukin-2, shows limited efficacy. Most patients do not respond, highlighting the need for novel treatments for this resistant cancer.

Area of Science:

  • Oncology
  • Immunotherapy
  • Medical Oncology

Background:

  • Advanced renal cell carcinoma (RCC) presents a significant therapeutic challenge.
  • Systemic therapies have historically shown limited success in treating metastatic RCC.

Purpose of the Study:

  • To review the efficacy of systemic therapies for advanced renal cell carcinoma (RCC).
  • To assess the outcomes of chemotherapy, immunotherapy, and combination treatments for metastatic RCC.

Main Methods:

  • Literature search of MEDLINE and CANCERLIT (1990-1998).
  • Review of treatment results for chemotherapy, immunotherapy (interferon-alpha, interleukin-2), combination therapies, and adjuvant treatments in renal cell carcinoma.

Main Results:

Related Experiment Videos

  • No single chemotherapy agent demonstrated significant response rates for advanced RCC.
  • Interferon-alpha and interleukin-2 showed low response rates (10-20%) with limited survival benefit.
  • Adjuvant interferon-alpha therapy did not improve survival in patients post-resection.

    • Conclusions:

    • Metastatic renal cell carcinoma remains largely resistant to current systemic therapies.
    • While some patients respond to interferon-alpha and/or interleukin-2, long-term survival is rare.
    • Development of novel agents and treatment strategies is crucial for improving outcomes in refractory RCC.